AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital
June 08 2021 - 07:00AM
AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”),
a clinical stage biopharmaceutical company specializing in the
development of targeted, non-systemic therapies
for gastrointestinal (GI) diseases, announced today that James
Sapirstein, Chief Executive Officer of AzurRx, will present at the
2021 BIO Digital. The virtual conference is taking place June 10-11
and June 14-18, 2021.
Details of the event are as follows:
Event: |
|
2021 BIO Digital |
Date: |
|
June 10-11 and June 14-18,
2021 |
Registration: |
|
https://www.bio.org/events/bio-digital/registration |
In a prerecorded presentation, Mr. Sapirstein
will provide an overview of AzurRx’s business and clinical
development programs and discuss anticipated 2021 and early 2022
milestones. The presentation will be available on demand to
registered conference attendees beginning at 9 a.m. ET on June 10,
2021.
Additionally, Mr. Sapirstein and members of the
AzurRx management team will be participating in virtual one-on-one
meetings with registered investors and pharmaceutical company
executives.
About AzurRx BioPharma,
Inc.AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical
stage biopharmaceutical company specializing in the development of
targeted, non-systemic therapies for gastrointestinal (GI)
diseases. The Company has a pipeline of three gut-restricted GI
assets. The lead therapeutic candidate is MS1819, a recombinant
lipase for the treatment of exocrine pancreatic insufficiency (EPI)
in patients with cystic fibrosis and chronic pancreatitis,
currently in two Phase 2 clinical trials. AzurRx is launching two
clinical programs using proprietary formulations of niclosamide, a
pro-inflammatory pathway inhibitor; FW-1022, for COVID-19
gastrointestinal infections and FW-420, for grade 1 Immune
Checkpoint Inhibitor-Associated Colitis and diarrhea in oncology
patients. The Company is headquartered in Boca Raton, Florida with
clinical operations in Hayward, California. For more information
visit www.azurrx.com.
Forward-Looking StatementThis
press release may contain certain statements relating to future
results which are forward-looking statements. It is possible that
the Company’s actual results and financial condition may differ,
possibly materially, from the anticipated results and financial
condition indicated in these forward-looking statements, depending
on factors including whether results obtained in preclinical and
nonclinical studies and clinical trials will be indicative of
results obtained in future clinical trials; whether preliminary or
interim results from a clinical trial will be indicative of the
final results of the trial; the size of the potential markets for
the Company’s drug candidates and its ability to service those
markets; and the Company’s current and future capital requirements
and its ability to raise additional funds to satisfy its capital
needs. Additional information concerning the Company and its
business, including a discussion of factors that could materially
affect the Company’s financial results are contained in the
Company’s Annual Report on Form 10-K for the year ended December
31, 2020 under the heading “Risk Factors,” as well as the Company’s
subsequent filings with the Securities and Exchange Commission. All
forward-looking statements included in this press release are made
only as of the date of this press release, and we do not undertake
any obligation to publicly update or correct any forward-looking
statements to reflect events or circumstances that subsequently
occur or of which we hereafter become aware.
For more information:
AzurRx BioPharma, Inc.777 Yamato RoadSuite 502Boca Raton,
Florida 33431Phone: (561) 589-7020info@azurrx.com
Media contact:
Tiberend Strategic Advisors, Inc.Johanna Bennett/Ingrid
Mezo(212) 375-2665/(646)
604-5150jbennett@tiberend.com/imezo@tiberend.com
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Mar 2023 to Mar 2024